In November, Novavax CEO John C. Jacobs detailed the company’s efforts beyond its COVID-19 vaccine, including expanding ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

​Pfizer Inc. (NYSE: PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing ...

Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.

The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...

Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results 1 and ...

An interim analysis of safety data showed no increased risk associated with Pfizer’s respiratory syncytial virus vaccine when ...

For the 20 years Blonski took Depo-Provera, she thought it was safe. Her lawsuit claims that had she known of the dangers associated with its use, she would not have taken the drug. In December 2025, ...